Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of QL0911 in pediatric primary immune thrombocytopenia
CTR20260847Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Qilu Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20260847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260847.